Published in Clin Cancer Res on October 01, 2007
Melanoma induction by ultraviolet A but not ultraviolet B radiation requires melanin pigment. Nat Commun (2012) 1.90
p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation. Pigment Cell Melanoma Res (2010) 1.21
Melanocytes as instigators and victims of oxidative stress. J Invest Dermatol (2014) 1.13
The p16(INK4A) tumor suppressor regulates cellular oxidative stress. Oncogene (2010) 1.12
Innate immune mechanisms in vitiligo: danger from within. Curr Opin Immunol (2013) 0.97
Use of oral N-acetylcysteine for protection of melanocytic nevi against UV-induced oxidative stress: towards a novel paradigm for melanoma chemoprevention. Clin Cancer Res (2009) 0.96
Role of melanin in melanocyte dysregulation of reactive oxygen species. Biomed Res Int (2013) 0.86
Efficacy of caffeic acid phenethyl ester (CAPE) in skin B16-F0 melanoma tumor bearing C57BL/6 mice. Invest New Drugs (2009) 0.86
ROS-mediated autophagy induced by dysregulation of lipid metabolism plays a protective role in colorectal cancer cells treated with gambogic acid. PLoS One (2014) 0.85
Selenium for the prevention of cutaneous melanoma. Nutrients (2013) 0.81
Oxidative stress as a therapeutic target in globoid cell leukodystrophy. Exp Neurol (2012) 0.80
The antioxidant paradox: what are antioxidants and how should they be used in a therapeutic context for cancer. Future Med Chem (2014) 0.79
Aspirin and other NSAIDs as chemoprevention agents in melanoma. Cancer Prev Res (Phila) (2014) 0.77
Melanocytes Affect Nodal Expression and Signaling in Melanoma Cells: A Lesson from Pediatric Large Congenital Melanocytic Nevi. Int J Mol Sci (2016) 0.75
A Phase II Randomized Placebo-Controlled Trial of Oral N-acetylcysteine for Protection of Melanocytic Nevi against UV-Induced Oxidative Stress In Vivo. Cancer Prev Res (Phila) (2016) 0.75
Tissue sulfhydryl groups. Arch Biochem Biophys (1959) 61.89
Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med (2004) 17.79
Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA (2007) 11.87
Management of cutaneous melanoma. N Engl J Med (2004) 9.52
Melanoma. N Engl J Med (2006) 8.80
High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med (2005) 7.20
N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med (2006) 5.63
A line of non-tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth. Int J Cancer (1987) 3.80
Oxidative stress in the pathogenesis of skin disease. J Invest Dermatol (2006) 3.16
Simultaneous establishment of monoclonal antibodies specific for either cyclobutane pyrimidine dimer or (6-4)photoproduct from the same mouse immunized with ultraviolet-irradiated DNA. Photochem Photobiol (1991) 2.84
Prospects for the use of antioxidant therapies. Drugs (1995) 2.57
Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum Mutat (2007) 2.35
Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol (1999) 2.21
UV-induced reactive oxygen species in photocarcinogenesis and photoaging. Biol Chem (1997) 1.51
Effect of (-)-epigallocatechin gallate, the main constituent of green tea, on lung metastasis with mouse B16 melanoma cell lines. Cancer Lett (1992) 1.36
The inherent cytotoxicity of melanin precursors: a revision. Biochim Biophys Acta (1994) 1.29
Scatter factor/hepatocyte growth factor as a regulator of skeletal muscle and neural crest development. Proc Natl Acad Sci U S A (1996) 1.27
Oxidative stress in malignant melanoma and non-melanoma skin cancer. Br J Dermatol (2003) 1.27
Increased sensitivity of melanocytes to oxidative stress and abnormal expression of tyrosinase-related protein in vitiligo. Br J Dermatol (2001) 1.19
Topical N-acetyl cysteine and genistein prevent ultraviolet-light-induced signaling that leads to photoaging in human skin in vivo. J Invest Dermatol (2003) 1.12
The role of the thiol N-acetylcysteine in the prevention of tumor invasion and angiogenesis. Int J Biol Markers (2000) 1.11
Melanocyte expression of survivin promotes development and metastasis of UV-induced melanoma in HGF-transgenic mice. Cancer Res (2007) 1.10
Proteomic and SAGE profiling of murine melanoma progression indicates the reduction of proteins responsible for ROS degradation. Proteomics (2006) 1.00
Melanin as a target for melanoma chemotherapy: pro-oxidant effect of oxygen and metals on melanoma viability. Pigment Cell Res (2003) 0.99
Use of N-acetyl cysteine to increase intracellular glutathione during the induction of antitumor responses by IL-2. J Immunol (1994) 0.96
Epidemiology and prevention of cutaneous melanoma. Curr Treat Options Oncol (2006) 0.94
Etiologic pathogenesis of melanoma: a unifying hypothesis for the missing attributable risk. Clin Cancer Res (2004) 0.92
The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study in Finland. Nutr Rev (1994) 0.89
Melanoma chemoprevention. J Am Acad Dermatol (2006) 0.88
Predominant formation of heavily pigmented dermal melanocytomas resembling 'animal-type' melanomas in hepatocyte growth factor (C57BL/6 x C3H)F1 mice following neonatal UV irradiation. J Cutan Pathol (2007) 0.87
Modulation of light-induced skin tumors by N-acetylcysteine and/or ascorbic acid in hairless mice. Carcinogenesis (2004) 0.86
Antioxidant administration to the mother prevents oxidative stress associated with birth in the neonatal rat. Life Sci (1994) 0.85
Vascular endothelial growth factor (VEGF) and melanoma. N-acetylcysteine downregulates VEGF production in vitro. Cytokine (2000) 0.84
A new and versatile method for determination of thiolamines of biological importance. J Chromatogr B Biomed Sci Appl (2001) 0.80
Amifostine aminothiols and protection of keratinocyte apoptosis and DNA damage. J Invest Dermatol (2002) 0.77
Mechanism of dismutation of superoxide produced during autoxidation of melanin pigments. Biochem Biophys Res Commun (1985) 0.77
Revised nomenclature and classification of inherited ichthyoses: results of the First Ichthyosis Consensus Conference in Sorèze 2009. J Am Acad Dermatol (2010) 2.87
Clinical and pathological features of pachyonychia congenita. J Investig Dermatol Symp Proc (2005) 2.45
Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. J Clin Oncol (2007) 2.19
Absence of senescence-associated beta-galactosidase activity in human melanocytic nevi in vivo. J Invest Dermatol (2007) 2.11
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs (2010) 2.09
Acrylic nail curing UV lamps: high-intensity exposure warrants further research of skin cancer risk. J Am Acad Dermatol (2013) 1.99
A variant of AESOP syndrome (adenopathy and extensive skin patch overlying a plasmacytoma) in a malignant blue-cell tumor. Arch Dermatol (2012) 1.92
The dysplastic nevus: from historical perspective to management in the modern era: part I. Historical, histologic, and clinical aspects. J Am Acad Dermatol (2012) 1.79
Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine. Mol Pharmacol (2004) 1.50
Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells. Oncogene (2004) 1.49
Comparative analysis of total body and dermatoscopic photographic monitoring of nevi in similar patient populations at risk for cutaneous melanoma. Dermatol Surg (2010) 1.46
Longitudinal assessment of the nevus phenotype in a melanoma kindred. J Invest Dermatol (2004) 1.44
Apoptosis regulators and responses in human melanocytic and keratinocytic cells. J Invest Dermatol (2003) 1.39
Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. J Clin Oncol (2011) 1.39
Lepromatous leprosy and reversal reaction in a Micronesian immigrant. Int J Dermatol (2003) 1.38
Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation. J Clin Oncol (2005) 1.35
Electrophilic prostaglandins and lipid aldehydes repress redox-sensitive transcription factors p53 and hypoxia-inducible factor by impairing the selenoprotein thioredoxin reductase. J Biol Chem (2002) 1.29
Survivin repression by p53, Rb and E2F2 in normal human melanocytes. Carcinogenesis (2007) 1.29
Endogenous dopamine regulates the rhythm of expression of the clock protein PER2 in the rat dorsal striatum via daily activation of D2 dopamine receptors. J Neurosci (2010) 1.28
Keratinocyte apoptosis in epidermal development and disease. J Invest Dermatol (2006) 1.28
Phospholipid scramblase 3 controls mitochondrial structure, function, and apoptotic response. Mol Cancer Res (2003) 1.26
A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer (2010) 1.24
Melanocortin 1 receptor genotype: an important determinant of the damage response of melanocytes to ultraviolet radiation. FASEB J (2010) 1.23
Metastatic melanoma in pregnancy: risk of transplacental metastases in the infant. J Clin Oncol (2003) 1.20
A variant in FTO shows association with melanoma risk not due to BMI. Nat Genet (2013) 1.17
Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma. Curr Opin Oncol (2006) 1.17
UVB-induced apoptosis drives clonal expansion during skin tumor development. Carcinogenesis (2004) 1.13
Androgen receptor expression patterns in Becker's nevi: an immunohistochemical study. J Am Acad Dermatol (2008) 1.12
Melanocyte expression of survivin promotes development and metastasis of UV-induced melanoma in HGF-transgenic mice. Cancer Res (2007) 1.10
Survivin enhances motility of melanoma cells by supporting Akt activation and {alpha}5 integrin upregulation. Cancer Res (2010) 1.06
Population-based prevalence of CDKN2A mutations in Utah melanoma families. J Invest Dermatol (2006) 1.05
Population-based analysis of prognostic factors and survival in familial melanoma. J Clin Oncol (2005) 1.04
Role of the apoptotic and mitotic regulator survivin in melanoma. Anticancer Res (2012) 1.03
Low rates of clinical recurrence after biopsy of benign to moderately dysplastic melanocytic nevi. J Am Acad Dermatol (2009) 1.03
Survivin expression in mouse skin prevents papilloma regression and promotes chemical-induced tumor progression. Cancer Res (2003) 1.00
Phosphorylation of mitochondrial phospholipid scramblase 3 by protein kinase C-delta induces its activation and facilitates mitochondrial targeting of tBid. J Cell Biochem (2007) 0.97
The depletion of DNA methyltransferase-1 and the epigenetic effects of 5-aza-2'deoxycytidine (decitabine) are differentially regulated by cell cycle progression. Epigenetics (2011) 0.97
Proliferation, apoptosis, and survivin expression in keratinocytic neoplasms and hyperplasias. Am J Dermatopathol (2004) 0.97
Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma. J Cutan Pathol (2015) 0.96
Role of phospholipid scramblase 3 in the regulation of tumor necrosis factor-alpha-induced apoptosis. Biochemistry (2008) 0.96
The dysplastic nevus: from historical perspective to management in the modern era: part II. Molecular aspects and clinical management. J Am Acad Dermatol (2012) 0.96
Use of oral N-acetylcysteine for protection of melanocytic nevi against UV-induced oxidative stress: towards a novel paradigm for melanoma chemoprevention. Clin Cancer Res (2009) 0.96
The effect of water solubility of solutes on their flux through human skin in vitro. Int J Pharm (2006) 0.96
Molecular classification of melanoma using real-time quantitative reverse transcriptase-polymerase chain reaction. Cancer (2005) 0.96
Pancreatic carcinoma surveillance in patients with familial melanoma. Arch Dermatol (2003) 0.95
Effects of trastuzumab on epidermal growth factor receptor-dependent and -independent human colon cancer cells. Int J Cancer (2004) 0.94
Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases. Cancer (2007) 0.94
Responses of human cells to ZnO nanoparticles: a gene transcription study. Metallomics (2011) 0.93
Diversity of pigmentation in cultured human melanocytes is due to differences in the type as well as quantity of melanin. Pigment Cell Res (2006) 0.93
Strategies for early melanoma detection: Approaches to the patient with nevi. J Am Acad Dermatol (2009) 0.93
A unique genome-wide association analysis in extended Utah high-risk pedigrees identifies a novel melanoma risk variant on chromosome arm 10q. Hum Genet (2011) 0.92
The marine alkaloid naamidine A promotes caspase-dependent apoptosis in tumor cells. Anticancer Drugs (2009) 0.92
A comparison of Binax NOW to viral culture and direct fluorescent assay testing for respiratory syncytial virus. Diagn Microbiol Infect Dis (2004) 0.91
Activation of dual apoptotic pathways in human melanocytes and protection by survivin. J Invest Dermatol (2006) 0.91
Digital dermoscopic monitoring of atypical nevi in patients at risk for melanoma. Dermatol Surg (2007) 0.90
Surgical margins for melanoma in situ. J Am Acad Dermatol (2012) 0.90
Recent advances in the understanding of the genetics, etiology, and treatment of Merkel cell carcinoma. Semin Oncol (2012) 0.90
Sampling of melanocytic nevi for research purposes: a prospective, pilot study to determine effect on diagnosis. J Am Acad Dermatol (2008) 0.90
Large cell non-Hodgkin's lymphoma masquerading as renal carcinoma with inferior vena cava thrombosis: a case report. J Med Case Rep (2011) 0.89
Colonization of adjacent stem cell compartments by mutant keratinocytes. Semin Cancer Biol (2005) 0.89
Human herpesvirus 8 and iron staining are useful in differentiating Kaposi sarcoma from interstitial granuloma annulare. Am J Clin Pathol (2007) 0.89
Conditional expression of 15-lipoxygenase-1 inhibits the selenoenzyme thioredoxin reductase: modulation of selenoproteins by lipoxygenase enzymes. J Biol Chem (2004) 0.89
Predominant formation of heavily pigmented dermal melanocytomas resembling 'animal-type' melanomas in hepatocyte growth factor (C57BL/6 x C3H)F1 mice following neonatal UV irradiation. J Cutan Pathol (2007) 0.87
Disseminated granuloma annulare accompanying mycobacterium tuberculosis lymphadenitis. Int J Dermatol (2004) 0.86
Role of melanin in melanocyte dysregulation of reactive oxygen species. Biomed Res Int (2013) 0.86
Phase 1 study of escalating-dose OncoGel (ReGel/paclitaxel) depot injection, a controlled-release formulation of paclitaxel, for local management of superficial solid tumor lesions. Anticancer Drugs (2007) 0.86
Differentiation of malignant melanoma from benign nevus using a novel genomic microarray with low specimen requirements. Arch Pathol Lab Med (2012) 0.85
Lentigo maligna/lentigo maligna melanoma: current state of diagnosis and treatment. Dermatol Surg (2006) 0.85
An appraisal of oral retinoids in the treatment of pachyonychia congenita. J Am Acad Dermatol (2011) 0.84
Survivin promotion of melanoma metastasis requires upregulation of α5 integrin. Carcinogenesis (2013) 0.84
Chondroid syringoma: case report of a highly unusual foot tumor. Foot Ankle Int (2010) 0.84
Melanoma. J Natl Compr Canc Netw (2006) 0.83
A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma. Cancer (2010) 0.83
Altered transcriptome signature of phenotypically normal skin fibroblasts heterozygous for CDKN2A in familial melanoma: relevance to early intervention. Oncotarget (2013) 0.83
Familial melanoma-associated mutations in p16 uncouple its tumor-suppressor functions. J Invest Dermatol (2012) 0.83
Onychodystrophy and tumor-stage mycosis fungoides confined to a single digit: report of a case and review of nail findings in cutaneous T-cell lymphoma. J Am Acad Dermatol (2008) 0.82
Proliferation, apoptosis, and survivin expression in a spectrum of melanocytic nevi. J Cutan Pathol (2005) 0.82
Failure to detect differences in proliferation status of nevi from CDKN2A mutation carriers and non-carriers. J Invest Dermatol (2002) 0.81
Selenium for the prevention of cutaneous melanoma. Nutrients (2013) 0.81
Use of proliferation rate, p53 staining and perforating elastic fibers in distinguishing keratoacanthoma from hypertrophic lichen planus: a pilot study. J Cutan Pathol (2012) 0.81
Management of melanoma brain metastases in the era of targeted therapy. J Skin Cancer (2011) 0.81